论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
评估康柏西普和地塞米松植入剂序贯治疗视网膜中央静脉阻塞(CRVO)继发难治性黄斑水肿的疗效:一项为期一年的随访研究
Authors Xing P, Zhang Y, Zhang Y, Wang S, Hu X, Wang M, Xia F, Zhao Y, Qu W, Meng B
Received 16 July 2024
Accepted for publication 24 September 2024
Published 30 September 2024 Volume 2024:18 Pages 2721—2730
DOI https://doi.org/10.2147/OPTH.S487248
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Peiyu Xing,1,* Yucheng Zhang,2,* Yong Zhang,1 Shaowei Wang,2 Xiaojia Hu,1 Meihua Wang,1 Fan Xia,1 Yang Zhao,1 Wei Qu,2 Bo Meng2
1Department of Ophthalmology, China Medical University the Fourth People’s Hospital of Shenyang, Shenyang, People’s Republic of China; 2Department of Ophthalmology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Bo Meng, Department of Ophthalmology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China, Email m18204507737@163.com
Purpose: The objective of this research was to assess the effectiveness and safety of using Conbercept injection and dexamethasone implant (DEX I) in sequence for treating refractory macular edema (ME) caused by central retinal vein occlusion (CRVO) in patients.
Methods: A study was conducted on 34 patients with persistent macular edema caused by central retinal vein occlusion, reviewing their medical history and interventions performed. Sequential implantation of DEX I was performed 1 week after the Conbercept injection. OCTA images were used to measure central retinal thickness (CRT), best-corrected visual acuity (BCVA), intraocular pressure (IOP), and pre- and post-treatment vessel density of the superficial capillary plexus (SCP) and deep capillary plexus (DCP), with a 1-year follow-up period.
Results: At the 12-month follow-up, participants demonstrated notable improvements in central retinal thickness and intraocular pressure (p < 0.05). Throughout the monitoring period, no significant differences were found in BCVA improvement or vessel density reduction (p > 0.05). Two patients required topical treatment to lower their intraocular pressure during the study period.
Conclusion: In conclusion, patients experiencing persistent ME due to secondary CRVO may benefit from transitioning to a treatment regimen involving Conbercept and DEX I, potentially resulting in a reduction in CRT. However, no significant improvement was observed in BCVA or deep and superficial capillary plexus vessel density.
Keywords: macular edema, sequential, central retinal thickness, best corrected visual acuity